The development of immunohistochemical assays to tailor immunotherapy treatment to other predictive biomarkers, such as PD-L1 expression levels, are also being pursued in the treatment of other cancer types, such as non-small cell lung cancer [80]. The gene discussed is CD274; the disease is cancer.